Attovia Therapeutics, Inc. (ATTO)
NASDAQ: ATTO · Real-Time Price · USD
19.31
-1.31 (-6.35%)
At close: Aug 25, 2026, 4:00 PM EDT
19.26
-0.05 (-0.26%)
After-hours: Aug 25, 2026, 7:30 PM EDT
Attovia Therapeutics Revenue
Attovia Therapeutics had revenue of $1.35M in the twelve months ending March 31, 2026. In the year 2025, Attovia Therapeutics had annual revenue of $1.35M.
Revenue (ttm)
$1.35M
Revenue Growth
n/a
P/S Ratio
615.47
Revenue / Employee
$30,682
Employees
44
Market Cap
830.89M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.35M | - | - |
| Dec 31, 2024 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
ATTO News
- 19 days ago - Attovia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 19 days ago - Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq - PRNewsWire
- 20 days ago - Attovia opens at $21.00, IPO priced at $17.00 - TheFly
- 20 days ago - Attovia indicated to open at $20, IPO priced at $17 - TheFly
- 20 days ago - Attovia indicated to open at $24, IPO priced at $17 - TheFly
- 21 days ago - Attovia Therapeutics Announces Pricing of Upsized Initial Public Offering - GlobeNewsWire
- 21 days ago - Goldman Sachs-backed Attovia eyes $731.5 million valuation in upsized US IPO - Reuters
- 5 weeks ago - Attovia Therapeutics Appoints John W. Smither to Board of Directors - GlobeNewsWire